Datapoint: Amgen Shores Up Otezla Patent Until 2028

In a victory against Sandoz and Zydus Pharmaceuticals, Amgen last week won a patent case protecting its blockbuster psoriasis drug Otezla from generic competition until 2028. For the treatment of psoriasis, Otezla holds covered or better status for 69% of all insured lives under the pharmacy benefit. It is not covered for 9.5% of lives.

SOURCE: MMIT Analytics, as of 9/22/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 26

Datapoint: Appeals Court Upholds Kentucky Medicaid Awards

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today